190 related articles for article (PubMed ID: 18707880)
1. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
[TBL] [Abstract][Full Text] [Related]
2. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
[TBL] [Abstract][Full Text] [Related]
3. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
4. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
5. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374
[TBL] [Abstract][Full Text] [Related]
6. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
7. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
8. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
Washburn WN
Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
[TBL] [Abstract][Full Text] [Related]
9. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
Santer R; Calado J
Clin J Am Soc Nephrol; 2010 Jan; 5(1):133-41. PubMed ID: 19965550
[TBL] [Abstract][Full Text] [Related]
10. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
12. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
13. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Ohtake Y; Sato T; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Yamaguchi M; Takami K; Yeu SY; Ahn KH; Matsuoka H; Morikawa K; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
J Med Chem; 2012 Sep; 55(17):7828-40. PubMed ID: 22889351
[TBL] [Abstract][Full Text] [Related]
14. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats.
Bickel M; Brummerhop H; Frick W; Glombik H; Herling AW; Heuer HO; Plettenburg O; Theis S; Werner U; Kramer W
Arzneimittelforschung; 2008; 58(11):574-80. PubMed ID: 19137908
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.
Putapatri SR; Kanwal A; Banerjee SK; Kantevari S
Bioorg Med Chem Lett; 2014 Mar; 24(6):1528-31. PubMed ID: 24556379
[TBL] [Abstract][Full Text] [Related]
16. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2).
van den Heuvel LP; Assink K; Willemsen M; Monnens L
Hum Genet; 2002 Dec; 111(6):544-7. PubMed ID: 12436245
[TBL] [Abstract][Full Text] [Related]
17. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
[TBL] [Abstract][Full Text] [Related]
20. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
